RASSF10 and sarcoma: Our present comprehensive work is the finalization of our previous research in smaller data sets in which we have shown that the promoter of RASSF10 is methylated in patient tumors samples of the adrenal gland [21], head and neck [19], sarcoma [19], pancreas carcinoma [19] and Merkel cell carcinoma [20].